Drug
CEND-1
CEND-1 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed250%
active_not_recruiting125%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_1
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
NCT05121038
completedphase_1
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
NCT05052567
recruitingphase_2
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
NCT06261359
completedphase_1
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
NCT03517176
Clinical Trials (4)
Showing 4 of 4 trials
NCT05121038Phase 1
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
NCT05052567Phase 1
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
NCT06261359Phase 2
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
NCT03517176Phase 1
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4